| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Choreoathetosis/spasticity episodic (paroxysmal choreoathetosis/spasticity) antibody; CSE antibody; DYT17 antibody; DYT18 antibody; DYT9 antibody; EIG12 antibody; erythrocyte/brain antibody; Erythrocyte/hepatoma glucose transporter antibody; facilitated glucose transporter member 1 antibody; Glucose transporter 1 antibody; Glucose transporter type 1 antibody; Glucose transporter type 1, erythrocyte/brain antibody; GLUT antibody; GLUT-1 antibody; GLUT1 antibody; GLUT1DS antibody; GLUTB antibody; GT1 antibody; GTG1 antibody; Gtg3 antibody; GTR1_HUMAN antibody; HepG2 glucose transporter antibody; HTLVR antibody; Human T cell leukemia virus (I and II) receptor antibody; MGC141895 antibody; MGC141896 antibody; PED antibody; RATGTG1 antibody; Receptor for HTLV 1 and HTLV 2 antibody; SLC2A1 antibody; Solute carrier family 2 (facilitated glucose transporter), member 1 antibody; Solute carrier family 2 antibody; Solute carrier family 2, facilitated glucose transporter member 1 antibody |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | Recombinant Human SLC2A1 protein |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a recombinant monoclonal antibody expressed in HEK293F cells. |
| Storage | |
| Target | |
| UniProt # |
Overview
This is a monoclonal anti-SLC2A1 antibody raised in Human, with confirmed utility in ELISA. It is designed to detect SLC2A1 protein in Human and supports researchers working in others contexts.
Key elements and design rationale
- Immunogen: Recombinant Human SLC2A1 protein — determines the epitope region; confirm compatibility with sample preparation and expected post-translational modifications.
- Host species (Human): Requires anti-human-IgG secondary reagents for indirect detection.
- Monoclonal format: Single-epitope binding provides high specificity and lot-to-lot reproducibility. Confirm epitope accessibility under your assay conditions.
- Isotype (IgG1): Matched secondary antibodies and isotype controls required. Compatible with standard Protein A/G purification workflows.
- Purification (Affinity chromatography): Enriches for specific immunoglobulin classes; reduces non-specific background vs. crude antisera.
Biological background
SLC2A1 (also referred to as Choreoathetosis/spasticity episodic (paroxysmal choreoathetosis/spasticity) antibody, CSE antibody, DYT17 antibody, DYT18 antibody, DYT9 antibody, EIG12 antibody, erythrocyte/brain antibody, Erythrocyte/hepatoma glucose transporter antibody, facilitated glucose transporter member 1 antibody, Glucose transporter 1 antibody, Glucose transporter type 1 antibody, Glucose transporter type 1, erythrocyte/brain antibody, GLUT antibody, GLUT-1 antibody, GLUT1 antibody, GLUT1DS antibody, GLUTB antibody, GT1 antibody, GTG1 antibody, Gtg3 antibody, GTR1_HUMAN antibody, HepG2 glucose transporter antibody, HTLVR antibody, Human T cell leukemia virus (I and II) receptor antibody, MGC141895 antibody, MGC141896 antibody, PED antibody, RATGTG1 antibody, Receptor for HTLV 1 and HTLV 2 antibody, SLC2A1 antibody, Solute carrier family 2 (facilitated glucose transporter), member 1 antibody, Solute carrier family 2 antibody, Solute carrier family 2, facilitated glucose transporter member 1 antibody) is a protein target studied in Human systems. Expression, subcellular localization, and post-translational modifications vary across cell types and disease states — factors critical to antibody-based detection design. Consult UniProt, NCBI Gene, and primary literature for current annotation of SLC2A1 biology in others.
Common research applications
- ELISA: Quantification of soluble target in biological fluids or culture supernatants. Ensure samples are within the linear detection range.
Notes for experimental interpretation
- Isotype controls: Use an isotype-matched (IgG1 from Human) control at equivalent concentration to assess non-specific background.
- Cross-reactivity: Confirm the clone does not cross-react with related family members under your assay conditions.
- Matrix effects: Sample matrix can affect performance; pilot dilution linearity and spike-recovery experiments are advised for quantitative studies.
- Species reactivity: Confirmed for Human. Extrapolation to untested species requires empirical validation.
This product is a recombinant monoclonal antibody expressed in HEK293F cells.
SLC2A1 is a protein target in Human biology. This monoclonal antibody raised in Human is designed to detect SLC2A1 in ELISA applications, with IgG1 isotype.
Reported reactive against Human. Immunogen derived from Human. Cross-reactivity with other species should not be assumed without documented data or empirical testing.
Reported for ELISA. Each format requires independent dilution optimization and appropriate controls. Unlisted applications require empirical testing.
This non-conjugated IgG1 antibody requires a compatible secondary. Select anti-human IgG secondary conjugated to your preferred reporter (HRP, AP, fluorophore, or biotin), matched to IgG1.
(1) Isotype control — IgG1 from Human at matching concentration; (2) Positive control — known SLC2A1-expressing cell/tissue; (3) Negative control — knockdown/knockout sample for specificity; (4) Dilution linearity — verify proportional signal decrease in your matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
